In our previous post, we explained that ustekinumab biosimilar pricing discounts of up to 90% still resulted in net prices of $3,000 or more per month. On August 18th, Accord Biopharma announced that it has launched its Imuldosa brand of ustekinumab biosimilar at a 92% wholesale acquisition cost (WAC) discount relative to Stelara. This bests … Continue reading Raising the Bar on Lower WAC Prices for Ustekinumab Biosimilars